Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Triple negative breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    231 result(s) found for: Triple negative breast cancer. Displaying page 9 of 12.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    EudraCT Number: 2017-003151-34 Sponsor Protocol Number: ET17-093 Start Date*: 2019-01-15
    Sponsor Name:Centre Léon Bérard
    Full Title: A multicenter, randomised, open-label Phase II study to evaluate the clinical benefit of a post-operative treatment associating radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitab...
    Medical condition: Triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006292 Breast neoplasms unspecified malignancy HLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004151-79 Sponsor Protocol Number: TRIO030 Start Date*: 2017-05-08
    Sponsor Name:Translational Research in Oncology (TRIO)
    Full Title: A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide (ODM-201)
    Medical condition: Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001521-43 Sponsor Protocol Number: 009246QM Start Date*: 2014-02-20
    Sponsor Name:Queen Mary University of London
    Full Title: A Phase II, double blind, randomised, placebo-controlled study of the AKT inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer
    Medical condition: Triple negative (ER-negative, PR-negative/unknown, HER2-negative) advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002934-32 Sponsor Protocol Number: D4884C00001 Start Date*: 2015-12-15
    Sponsor Name:AstraZenenca AB
    Full Title: A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
    Medical condition: Adult patients (age ≥18 years) with advanced and metastatic solid tumors including but not limited to histologically or cytologically documented UBC, PDAC, or TNBC.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071664 Bladder transitional cell carcinoma metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002038-21 Sponsor Protocol Number: CO40115 Start Date*: 2018-05-01
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE-NEGATI...
    Medical condition: Triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001471-23 Sponsor Protocol Number: UZBRU_VHH2_1 Start Date*: 2019-02-06
    Sponsor Name:UZ Brussel
    Full Title: Phase I/IIa study to evaluate the safety, biodistribution, radiation dosimetry and tumor imaging potential of 68GaNOTA-Anti-MMR-VHH2, a new radiopharmaceutical for in vivo imaging of Tumour-Associa...
    Medical condition: Tumour associated macrophages found in tumour lesions of two cancer types: breast cancer or melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005461-13 Sponsor Protocol Number: CLEE011X2106 Start Date*: 2013-10-12
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase Ib/II trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with estrogen receptor positive Her2 negative locally advanced or metas...
    Medical condition: estrogen receptor positive, Her2- locally advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001553-14 Sponsor Protocol Number: BGB-290-103 Start Date*: 2018-06-29
    Sponsor Name:BeiGene USA, Inc.
    Full Title: A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors
    Medical condition: Locally Advanced or Metastatic Solid Tumors (ovarian cancer, triple negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC), small cell lung cancer (SCLC), and gastri...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-004005-16 Sponsor Protocol Number: D081KC00001 Start Date*: 2016-03-01
    Sponsor Name:Astra Zeneca AB
    Full Title: A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors
    Medical condition: Initial stage cohort: SCLC germline BRCA mutated (gBRCAm) metastatic human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) gBRCAm platinum sensitive relapsed ovarian cancer (O...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    21.1 100000004864 10071114 Metastatic gastric adenocarcinoma LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    21.1 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000558-71 Sponsor Protocol Number: 9090-11 Start Date*: 2012-07-25
    Sponsor Name:Synta Pharmaceuticals Corp.
    Full Title: An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women with Breast Cancer
    Medical condition: HER2 positive, triple negative breast cancer (TNBC) and hormone-receptor (ER/PR)-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    16.1 10022891 - Investigations 10054057 Progesterone receptor assay positive PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-000850-78 Sponsor Protocol Number: IB2019-01 Start Date*: 2021-01-20
    Sponsor Name:Institut Bergonié
    Full Title: Atezolizumab combined with BDB001 and immunogenic radiotherapy in participants with advanced solid tumors.
    Medical condition: - pancreatic cancer - virus-associated tumors - non-small cell lung cancer - soft-tissue sarcoma - bladder cancer - Triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005012 Bladder cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001779-54 Sponsor Protocol Number: GEICAM/2015-04 Start Date*: 2017-01-05
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer (ABC). “PANGEA-Breast”
    Medical condition: Patients with HER2-negative advanced breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-002613-31 Sponsor Protocol Number: 009896QM Start Date*: 2015-04-27
    Sponsor Name:Queen Mary University of London
    Full Title: A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers.
    Medical condition: Triple-Negative Breast Cancer Non-squamous Small Cell Lung Cancer Squamous Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-004696-41 Sponsor Protocol Number: 2020/3130 Start Date*: 2021-11-04
    Sponsor Name:Gustave Roussy
    Full Title: Randomized Preoperative Breast Immune Selection (BIS) Program in patients with early breast cancer
    Medical condition: Newly diagnosed, non-metastatic early triple negative or HER2+ breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001959-37 Sponsor Protocol Number: E7449-E044-101 Start Date*: 2011-10-17
    Sponsor Name:Eisai Limited
    Full Title: An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combinat...
    Medical condition: Advanced solid tumors (including ovarian cancer, triple negative breast cancer, and advanced melanoma) and B-cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033130 Ovarian cancer NOS LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10045992 Unspecified leukemia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003402-46 Sponsor Protocol Number: CAN04CLIN005 Start Date*: 2021-09-23
    Sponsor Name:Cantargia AB
    Full Title: A randomized non-comparative open-label phase 1b/2 study of nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. “TRIFOUR study”.
    Medical condition: Unresectable locally advanced or metastatic triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10084066 Triple negative breast cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001269-18 Sponsor Protocol Number: D-IVa/D-IVb Start Date*: 2013-12-19
    Sponsor Name:Universitätsklinikum Ulm (AöR)
    Full Title: A multicenter phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs).
    Medical condition: Everolimus/ribociclib cohort (D-IVa): Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and ind...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-005157-21 Sponsor Protocol Number: PH002-TP-II Start Date*: 2017-09-21
    Sponsor Name:Palleos healthcare GmbH
    Full Title: A prospective, randomized, multicenter, open-label comparison of pre-surgical combination of trastuzumab and pertuzumab with concurrent taxane chemotherapy or endocrine therapy given for twelve wee...
    Medical condition: Early HER2+/HR+ (triple positiveTP) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005223-21 Sponsor Protocol Number: D926PC00001 Start Date*: 2022-06-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in Firs...
    Medical condition: Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003115-21 Sponsor Protocol Number: 2018/2798 Start Date*: 2019-02-19
    Sponsor Name:Gustave Roussy
    Full Title: A phase II whole exoMe sequencing-bAsed baskeT trIal for combination therapy with durvaLumab (anti-PDL1) (MEDI4736) anD tremelimumAb (anti-CTLA4) in patients with metastatic solid tumors
    Medical condition: Metastatic colorectal adenocarcinoma (without microsatellite instability (not MSI)), triple negative breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066350 Adenocarcinoma of the gastrooesophageal junction LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 19:44:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA